Abstract 1247P
Background
Volatile organic compounds (VOCs) are known to be associated with lung cancer, and EGFR mutations are common in lung adenocarcinoma. In this study, we aimed to investigate the potential of VOCs analysis as a non-invasive method for early detection of EGFR mutation.
Methods
We collected breath samples from 114 EGFR wild-type lung adenocarcinoma patients and 132 EGFR mutant lung adenocarcinoma patients and analyzed them using High-Pressure Photon Ionization Time-of-Flight Mass Spectrometry (HPPl-TOFMS) to detect VOCs. A detection model for EGFR mutation based on VOC analysis was established using the eXtreme Gradient Boosting (XGB) algorithm. For building the EGFR mutation detection model, all the samples were randomly split into a training set, validation set, and test set with a ratio of 5:2:3.
Results
The top ten VOC ions which were significantly different between the EGFR mutant lung adenocarcinoma patients and patients without EGFR mutation were displayed in the table (P < 0.05). The discrimination power of each VOC was relatively limited. Among them, 2-Ethyl-4,5-dimethylthiazole had the highest accuracy with an area under the receiver operating characteristic curve (AUC) of 0.829 (95%CI: 0.744-0.974). With the combination of these 10 VOC ions, the model performs well. The AUC for the combination model was 0.895 (95% CI: 0.810-0.980) in the validation cohort, while the AUC in the test set was 0.849 (95% CI: 0.769-0.930), indicating good diagnostic accuracy, with sensitivity and specificity of 70.7% (95% CI: 56.6%, 84.4%) and 71.4% (95% CI: 56.2%, 86.6%). Table: 1247P
The top 10 VOC ions related to EGFR mutation in lung adenocarcinoma
Chemicals | Peak area | P-value | |
EGFR mut | RGFR wild | ||
Cyclohexanone oxime | 242.6±103.4 | 139.1±234.1 | <0.001 |
Dimethoxybenzene | 522.7±1730.2 | 200.0±256.6 | 0.017 |
Tert-Butyl methyl ether | 667.5±1655.3 | 278.4±302.0 | 0.006 |
2-Ethyl-4,5-dimethylthiazole | 659.0±1762.2 | 329.7±730.8 | 0.039 |
Trimethylbenzene | 375.1±617.7 | 202.9±185.6 | <0.001 |
Salicylamide | 310.6±332.9 | 203.0±187.3 | <0.001 |
p-cymene/Cinnamyl alcohol | 300.5±1002.5 | 123.5±130.7 | 0.038 |
L-serine/D-serine | 706.2±515.0 | 359.9±318.0 | <0.001 |
1-Propanethiol | 2005.3±1609.7 | 1419.7±1673.0 | 0.002 |
4-Methylanisole/2-Methylanisole | 402.1±314.4 | 180.1±220.1 | <0.001 |
Conclusions
Our study suggested that VOCs analysis might be useful as non-invasive methods for early detection of EGFR mutations in lung adenocarcinoma. Further studies are needed to validate the accuracy of our model.
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
The Chinese National Natural Science Foundation Project; China Postdoctoral Science Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1794P - Prognostic role of metastatic site in patients with de novo metastatic prostate cancer: A population-based analysis in new hormonal agents era
Presenter: Emre Yekeduz
Session: Poster session 14
1795P - China ARCHES: A multicenter phase III randomized double-blind placebo (PBO)-controlled efficacy and safety trial of enzalutamide (ENZA) + androgen deprivation therapy (ADT) vs PBO + ADT in Chinese patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC)
Presenter: Gongqian Zeng
Session: Poster session 14
1796P - Real-world analysis of metastatic hormone-sensitive prostate cancer: Are randomized clinical trials more trustworthy? Insights from PIONEER, the European network of excellence for big data in prostate cancer
Presenter: Juan Gómez Rivas
Session: Poster session 14
1797P - Application of novel machine learning model in [68Ga] Ga-PSMA-11 PET/CT: Predicting survival in oligometastatic prostate cancer patients
Presenter: Mikaela Dell'Oro
Session: Poster session 14
1800P - Differential tumor gene-expression profiling of patients (pts) with de-novo metastatic castration-sensitive prostate cancer (dn-mCSPC) versus (vs.) mCSPC relapsing after prior localized therapy (PLT-mCSPC)
Presenter: Vinay Mathew Thomas
Session: Poster session 14
1803P - Phase I/II study of bavdegalutamide, a PROTAC androgen receptor (AR) degrader in metastatic castration-resistant prostate cancer (mCRPC): Radiographic progression-free survival (rPFS) in patients (pts) with <italic>AR</italic> ligand-binding domain (LBD) mutations
Presenter: Daniel Petrylak
Session: Poster session 14